

May 6, 2019



## Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai

**DURHAM, NC / ACCESSWIRE / May 6, 2019** /[Heat Biologics, Inc.](#) (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today announced that John Prendergast, Heat Biologic's Lead Board member, is scheduled to present at the ChinaBio 2019 conference on Thursday, May 9<sup>th</sup>, at 2:15 PM China Standard Time (CST), which is being held at Pudong Ballroom 5, 3F, Kerry Hotel in Pudong, Shanghai, China.

Additional information on the conference is available at:<https://ebdgroup.knect365.com/chinabio-partnering/>

### **About Heat Biologics, Inc.**

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform ("TCAP") produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer.

Our *ComPACT* technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®) and with Merck's pembrolizumab (Keytruda®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. For more information, please visit [www.heatbio.com](http://www.heatbio.com).

### **Media and Investor Relations Contact**

David Waldman  
+1 919 289 4017  
[investorrelations@heatbio.com](mailto:investorrelations@heatbio.com)

**SOURCE:** Heat Biologics, Inc.